SCHEMBL25844172

SCHEMBL25844172

COc1cc(-c2cn(C)c(=O)c3[nH]ncc23)cc(OC)c1CN1CCC(C(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 8/20 0.43
BRD9 Q9H8M2 15/20 0.41
BRD7 Q9NPI1 7/20 0.41
TAF1 P21675 1/20 0.41
TGFBR1 P36897 1/20 0.41
BRPF1 P55201 1/20 0.41
ACVR1 Q04771 1/20 0.41
BPTF Q12830 1/20 0.41
TAF1L Q8IZX4 1/20 0.41
CREBBP Q92793 1/20 0.41
CECR2 Q9BXF3 1/20 0.41
BAZ2B Q9UIF8 1/20 0.41
ATAD2B Q9ULI0 1/20 0.41
BRD2 P25440 2/20 0.40
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23798711 0.95 BRD4 (0.41) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL23798710 0.95 BRD4 (0.42) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL25091531 0.94 BRD4 (0.42) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL23798715 0.91 BRD9 (0.46) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL25091533 0.90 BRD4 (0.46) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL25091959 0.88 BRD9 (0.43) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL23799092 0.88 BRD9 (0.45) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL23798047 0.88 BRD9 (0.43) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL23798716 0.87 BRD4 (0.42) BRD4BRD9BRD7TAF1TGFBR1
SCHEMBL25091527 0.86 BRD9 (0.46) BRD4BRD9BRD7TAF1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 BRD4 17/4885BRD9 1/4885BRD7 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.